NCT01487174 2022-05-13KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyKadmon Corporation, LLCPhase 3 Terminated8 enrolled